Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S-arrestin peptide 291–310-specific CD4+ T cells are a specialized population of helper T lymphocytes that recognize a specific 20-amino acid sequence (residues 291–310) of the retinal S-arrestin (S-Ag) protein (PubMed: 1723134). These cells play a central role in the pathogenesis of autoimmune uveitis, an inflammatory condition of the eye, by migrating to the retina and orchestrating an immune attack against photoreceptor cells (PubMed: 8496328). In experimental models, such as Experimental Autoimmune Uveitis (EAU), these T cells are often used to induce disease or serve as the primary target for evaluating novel immunotherapies (PubMed: 15546388). Therapeutic interventions targeting these cells aim to either suppress their activation using traditional immunosuppressants like Cyclosporine or induce antigen-specific tolerance to prevent the autoimmune destruction of ocular tissues (PubMed: 2461132). Understanding the activation and regulation of these specific T cells is crucial for developing precision treatments for non-infectious uveitis. These cells are characterized by their expression of CD4 and their specific T-cell receptor (TCR) affinity for the S-Ag 291-310 epitope presented on MHC class II molecules.
Inhibition of T-cell activation via calcineurin inhibition, suppression of pro-inflammatory cytokine production, and induction of antigen-specific peripheral tolerance or anergy.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-arrestin peptide 291–310-specific CD4+ T lymphocyte (Arr 291–310 CD4+ T cell).